LifeStance CPO reports RSU grant and tax withholding

LifeStance Health Group, Inc. Chief People Officer Ann Varanakis reported two equity transactions in company common stock.

Accepted by SEC EDGAR 03/09/2026 - 08:08 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

LifeStance Health Group, Inc. Chief People Officer Ann Varanakis reported two equity transactions in company common stock. On March 5, 2026, she acquired 86,331 restricted stock units as a grant, each representing a contingent right to receive one share of common stock.

On March 6, 2026, 21,566 shares were withheld by the company at a price of $6.93 per share to cover tax obligations upon settlement of vested RSUs. The footnote states this withholding reduced shares delivered to her and did not involve any open‑market sale.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Varanakis Ann

Role Chief People Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	21,566	$6.93	$149K
Grant/Award	Common Stock	86,331	$0.00	$0.00

Holdings After Transaction: Common Stock — 380,375 shares (Direct)

Footnotes (2)

1. F1. Includes 86,331 restricted stock units ("RSUs") granted on March 5, 2026. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
2. F2. Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations in connection with the net settlement of RSUs that vested on March 6, 2026. The shares withheld represent a reduction of shares issued to the Reporting Person upon settlement of vested RSUs and do not constitute any open-market sale.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did LFST Chief People Officer Ann Varanakis report?

Ann Varanakis reported an RSU grant and a tax-related share withholding. She received 86,331 restricted stock units on March 5, 2026, and had 21,566 shares withheld on March 6, 2026 to satisfy tax obligations tied to vested RSUs.

Were Ann Varanakis’s LFST share transactions open-market buys or sells?

The filing shows no open-market buys or sells. It reports an 86,331-share RSU grant and a 21,566-share withholding by the issuer for taxes, with a footnote explicitly stating the withholding does not constitute any open-market sale of LifeStance common stock.

How many LifeStance RSUs did Ann Varanakis receive in this Form 4 filing?

She received 86,331 restricted stock units. The filing explains each RSU represents a contingent right to receive one share of LifeStance Health Group common stock, reflecting a stock-based compensation award granted on March 5, 2026 to the Chief People Officer.

Why were 21,566 LFST shares withheld from Ann Varanakis on March 6, 2026?

21,566 shares were withheld to satisfy tax withholding obligations on RSUs that vested March 6, 2026. The filing notes these withheld shares reduced the number of shares delivered to her and do not represent any open-market sale of LifeStance stock.

How many LifeStance shares did Ann Varanakis directly hold after these transactions?

After the RSU grant, she directly held 401,941 shares, then 380,375 shares following tax withholding. The filing’s totals reflect adjustments from the 86,331-share RSU grant and the 21,566-share issuer withholding tied to RSU settlement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Varanakis Ann

(Last) (First) (Middle)

C/O LIFESTANCE HEALTH GROUP, INC.

4800 N. SCOTTSDALE ROAD, SUITE 2500

(Street)

SCOTTSDALE AZ 85251

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LifeStance Health Group, Inc. [ LFST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief People Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/05/2026		A		86,331(1)	A	$0	401,941	D
Common Stock	03/06/2026		F(2)		21,566	D	$6.93	380,375	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes 86,331 restricted stock units ("RSUs") granted on March 5, 2026. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

2. Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations in connection with the net settlement of RSUs that vested on March 6, 2026. The shares withheld represent a reduction of shares issued to the Reporting Person upon settlement of vested RSUs and do not constitute any open-market sale.

	By: /s/ Ryan Pardo, Attorney-in-Fact	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.